Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Selinexor, Pomalidomide and Dexamethasone vs Elotuzumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma SELINEXOR

What's the purpose of this trial?

The goal of this clinical trial is to learn more about the safety and effectiveness of Selinexor in treating relapsed or refractory multiple myeloma. Researchers seek to accomplish this by comparing two different regimens, selinexor combined with pomalidomide and dexamethasone, and elotuzumab combined with pomalidomide and dexamethasone.

Pomalidomide and dexamethasone are oral drugs that are used to treat relapsed or refractory multiple myeloma. Pomalidomide and dexamethasone in combination with elotuzumab, which is given intravenously, is a standard therapy for relapsed or refractory multiple myeloma. Selinexor is an oral drug, and the all-oral combination of selinexor, pomalidomide, and dexamethasone, where none of the study drugs requires and infusion or injection, is being evaluated in this study and compared to elotuzumab, pomalidomide, and dexamethasone.

This trial is currently open and accepting patients.

What will happen during the trial?

This trial is open-label, which means that both the participants and health care professionals will know which treatments and doses they are receiving. Participants may continue to receive treatment as long as they do not develop bad side effects, and their myeloma does not get worse.

This clinical trial is being conducted in two different parts. In Part 1, researchers studied how safe and effective two different doses of selinexor were in combination with pomalidomide and dexamethasone compared to elotuzumab, pomalidomide and dexamethasone. Part 1 of this trial is no longer enrolling. 

Part 2 of this clinical trial is currently enrolling, and is organized into two different groups, with a total of approximately 220 participants. In Part 2, researchers will compare the best dose of selinexor , pomalidomide and dexamethasone to elotuzumab, pomalidomide and dexamethasone in a larger group of patients.

Participants in Part 2 will be randomly assigned into one of two groups. Both groups will receive treatment organized into 28 day cycles.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • have measurable multiple myeloma disease as defined by the trial criteria.
  • have received at least one, but no more than four prior lines of therapy for your myeloma.
  • must have received therapy with an anti-CD38 antibody (e.g., daratumumab [Darzalex], isatuximb [Sarclisa]) as part of their immediate last line of therapy prior to joining this study.
  • must have previously received at least two consecutive cycles of lenalidomide and a proteasome inhibitor (e.g., bortezomib [Velcade], carfilzomib [Kyprolis], ixazomib [Ninlaro]) given alone or in combination. 
  • must not have had prior treatment with a Selective Inhibitor of Nuclear Export (SINE) compound, pomalidomide, or elotuzumab.
  • must not have had an autologous stem cell transplant in the previous 100 days, or an allogeneic stem cell transplant in the previous four months.
  • must have adequate bone marrow, liver, kidney function as defined by the trial criteria.

Additional Trial Information

Phase 3

Enrollment: 222 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


University of Arizona Cancer Center

Tucson, AZ

Not Yet Accepting


University of California San Francisco (Fresno Campus)

Fresno, CA

Not Yet Accepting

Kaiser Permanente Orange County Irvine Medical Center

Irvine, CA

Not Yet Accepting

Los Angeles Cancer Network (Los Angeles)

Los Angeles, CA

Open and Accepting

James R Berenson, MD, Inc.

West Hollywood, CA

Open and Accepting

The Oncology Institute of Hope and Innovation - Whittier

Whittier, CA

Open and Accepting


University of Colorado Health - Poudre Valley Hospital Poudre Valley Hospital

Fort Collins, CO

Not Yet Accepting


Florida Cancer Specialists South

Fort Myers, FL

Not Yet Accepting

Florida Cancer Specialists - North - St. Petersburg North

St. Petersburg, FL

Not Yet Accepting

Florida Cancer Specialists - Panhandle Tallahassee East

Tallahassee, FL

Not Yet Accepting

Florida Cancer Specialists - East - West Palm Beach West Palm Beach

West Palm Beach, FL

Not Yet Accepting


Hawaii Cancer Care - Waterfront Plaza

Honolulu, HI

Open and Accepting


June E Nylen Cancer Center

Sioux City, IA

Not Yet Accepting


Hematology Oncology Clinic

Baton Rouge, LA

Open and Accepting



Van Elslander Cancer Center

Grosse Pointe Woods, MI

Not Yet Accepting


Nebraska Hematology Oncology

Lincoln, NE

Open and Accepting

New Jersey

MD Anderson Cancer Center at Cooper Cooper University Hospital

Camden, NJ

Not Yet Accepting

North Carolina

East Carolina University Vidant Cancer Care Eddie and Jo Allison Smith Tower

Greenville, NC

Not Yet Accepting


Tower Health Reading Hospital

West Reading, PA

Open and Accepting

South Carolina

Medical University of South Carolina

Charleston, SC

Not Yet Accepting

Gibbs Cancer Center and Research Spartanburg Medical Center

Spartanburg, SC

Not Yet Accepting


Renovatio Clinical

The Woodlands, TX

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

Learn more about how we work with trial sponsors